Nalaganje...
Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
Anti-tumour immune activation by checkpoint inhibitors leads to durable responses in a variety of cancers, but combination approaches are required to extend this benefit beyond a subset of patients. In preclinical models tumour-derived VEGF limits immune cell activity while anti-VEGF augments intra-...
Shranjeno v:
izdano v: | Nat Commun |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
Format: | Artigo |
Jezik: | Inglês |
Izdano: |
Nature Publishing Group
2016
|
Teme: | |
Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5013615/ https://ncbi.nlm.nih.gov/pubmed/27571927 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/ncomms12624 |
Oznake: |
Označite
Brez oznak, prvi označite!
|